Ed KahnDirector of Strategic Business Development

Edward Kahn has served as Director of Strategic Business Development for the Cures Within Reach Patient Impact Initiative since late 2010. Ed is an intellectual property expert and the founding president of EKMS, Inc., a company known for pioneering novel IP management techniques for two decades.

Ed sold EKMS to a publicly traded company in 2004, but came out of retirement to apply his licensing skills and tech transfer experience at CWR, where he will help patients access effective "new" treatments more quickly and affordably through Rediscovery Researchâ„¢.

The repurposed drugs and other Rediscovery Research approaches established by Cures's research partners are often safer, more effective and cheaper than the current Standard of Care, but there is often a gap between publication of research results and adoption of the "rediscovered" treatment in the clinic by physicians and patients. Ed works with public and private sector life sciences organizations to devise creative new business methods aimed at ensuring that life-saving therapies reach patients as soon as feasible.

Ed has presented and written extensively on licensing and IP strategy for John Wiley, Euromoney Publishing, Forbes, the Wall Street Journal, the Boston Globe, Mass High Tech, the Licensing Executives Society (LES) and the Boston Patent Lawyers' Association. His recent book, "Innovate or Perish: Managing the Enduring Technology Company in the Global Market", focuses on the challenge of IP management in today's evolving innovation environment.

Sign up for our eNewsletter today!


First Name

Cures Within Reach



Friday the 19th. copyright 2015 Cures Within Reach.